Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)-Reference-Cited by-同舟云学术

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Published:2019-11-20 Issue:2 Volume:9 Page:432-439
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Vergnenegre Alain¹^ORCID,Geier Margaux²,Guisier Florian³,Lamy Regine⁴,Comet Bénédicte⁵,Le Garff Gwenaelle⁶,Do Pascal⁷,Janicot Henri⁸,Morel Hugues⁹,Decroisette Chantal¹⁰,Andre Michel¹¹,Falchero Lionel¹²,Paleiron Nicolas¹³,Monnet Isabelle¹⁴,

Affiliation:

1. CHU Dupuytren UOTC Limoges France

2. Department of Pneumology CHU Morvan Brest France

3. Department of Pneumology, Thoracic Oncology and Respiratory Intensive Care – CHU de Rouen Hôpital Charles Nicolle Rouen France

4. Department of Oncology Centre Hospitalier Bretagne Sud‐Lorient Lorient France

5. Department of Oncology Centre Catalan d'Oncologie Perpignan France

6. Department of Pneumology CH Yves Le Foll Saint‐Brieuc France

7. Centre François Baclesse Caen France

8. Department of Pneumology CHU Hôpital Montpied Clermont Ferrand France

9. Department of Pneumology CHR Orléans Orléans France

10. Department of Pneumology Centre Hospitalier Annecy‐Genevoise Pringy France

11. Department of Pneumology CHU La Réunion Saint‐Denis France